Fibrogen, Inc.

The Scripps Research Institute

Novabay Pharmaceuticals, Inc.

Blackthorn Therapeutics, Inc.

Lycia Therapeutics, Inc.

Neumora Therapeutics, Inc.

Eric Douglas Turtle

Lee Allen Flippin

Michael P Arend

Wen-Bin Ho

Xiaohui Du

Volkmar Guenzler-Pukall

Min Wu

Shaojiang Deng

Heng Cheng

Robert M Jones

Edward Roberts

Hugh Rosen

Miguel A Guerrero

Donogh John Roger O'Mahony

Mariangela Urbano

Charles Francavilla

Lee Robert Wright

Timothy Shiau

Eddy Low

Candace Mae Laxamana

Xianrui Zhao

Rakesh K Jain

Craig J Mossman

Web-Bin Ho

Jason Gustaf Lewis

Justin T Ernst

Garrick Kenneth Packard

Brett Bradley Busch

Ramin Najafi

Danny Ng

Wen-bin Ho

The present disclosure provides a class of compounds including a ligand moiety that specifically binds to a cell surface asialoglycoprotein receptor (ASGPR). The cell surface ASGPR binding compounds can trigger the receptor to internalize into the cell a bound compound. The ligand moieties of this disclosure can be linked to a variety of moieties of interest without impacting the specific binding to, and function of, the cell surface receptor ASGPR. Also provided are compounds that are conjugates of the ligand moieties linked to a biomolecule, such as an antibody, which conjugates can harness cellular pathways to remove specific proteins of interest from the cell surface or from the extracellular milieu. Also provided herein methods of using the conjugates to target a polypeptide of interest for sequestration and/or lysosomal degradation.

ASGPR cell surface receptor binding compounds and conjugates

Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof: wherein X, Y, R, R, R, R, R, R, Rand Rare as defined herein.

Kappa opioid receptor antagonists and products and methods related thereto

The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.

Nitrogen-containing heteroaryl compounds and methods of use thereof

Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof: wherein X, Y, R, R, R, RR, R, Rand Rare as defined herein.

The present application describes compounds of Formula I: which are antimicrobial agents, including antibacterial, disinfectant, antifungal, germicidal and/or antiviral agents.

Substituted N,N-dihaloamines as antimicrobials

The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure: 

Cyanoisoquinoline compounds and methods of use thereof

The present invention relates to novel compounds, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).

Thiochromene derivatives as HIF hydroxylase inhibitors

The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF).

Thienopyridine compounds, and methods of use thereof

The invention monitors the neutralization process involving hydrogen peroxide solution and a hydrogen peroxide neutralization catalyst and compares measured values with theoretical values. The system monitors the chemical reaction and notifies the user of the neutralization status. In an exemplary embodiment, the initial hydrogen peroxide solution concentration is neutralized with a palladium catalyst after a period of time. A microcontroller analyzes the measurements and displays the neutralization process results using colored LED lights and/or text or images on a LCD display. In one embodiment, an apparatus adapted for use with a cleaning solution used to clean a medical device may include a trigger, a processing device in communication with the trigger, and a display device. The processing device provides a trigger count and the display device communicates with the processing device and displays a message based on the count.

Contact lens cleaning system with monitor

Growing community of inventors

Belmont, CA, United States of America

Eric Douglas Turtle